This workshop explores how targeting format, payload, and linker choices interact to shape efficacy, safety, and clinical strategy, by bringing together a unique audience across the targeting format and payload landscape to understand where different modalities can complement one another for success.

• Understand how targeting format (monoclonal, bispecific, antibody fragment, peptide) influences payload selection and mechanism of action
• Evaluate whether monoclonal antibodies remain optimal for emerging payloads such as degraders and oligonucleotides
• Compare design trade-offs between bispecific targeting and payload potency, stability, and exposure
• Explore compatibility challenges and linker considerations when combining new payload types with novel scaffolds
• Develop an integrated design framework that connects discovery, chemistry, and translational perspectives